These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

961 related articles for article (PubMed ID: 25697677)

  • 1. Colistin, mechanisms and prevalence of resistance.
    Bialvaei AZ; Samadi Kafil H
    Curr Med Res Opin; 2015 Apr; 31(4):707-21. PubMed ID: 25697677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.
    Li J; Nation RL; Milne RW; Turnidge JD; Coulthard K
    Int J Antimicrob Agents; 2005 Jan; 25(1):11-25. PubMed ID: 15620821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colistin and its role in the Era of antibiotic resistance: an extended review (2000-2019).
    El-Sayed Ahmed MAE; Zhong LL; Shen C; Yang Y; Doi Y; Tian GB
    Emerg Microbes Infect; 2020 Dec; 9(1):868-885. PubMed ID: 32284036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colistin: re-emergence of the 'forgotten' antimicrobial agent.
    Dhariwal AK; Tullu MS
    J Postgrad Med; 2013; 59(3):208-15. PubMed ID: 24029199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.
    Falagas ME; Kasiakou SK
    Clin Infect Dis; 2005 May; 40(9):1333-41. PubMed ID: 15825037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?
    Ardebili A; Izanloo A; Rastegar M
    Expert Rev Anti Infect Ther; 2023 Apr; 21(4):387-429. PubMed ID: 36820511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. History, Chemistry and Antibacterial Spectrum.
    Velkov T; Thompson PE; Azad MAK; Roberts KD; Bergen PJ
    Adv Exp Med Biol; 2019; 1145():15-36. PubMed ID: 31364069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multidrug-resistant Gram-negative infections: what are the treatment options?
    Giamarellou H; Poulakou G
    Drugs; 2009 Oct; 69(14):1879-901. PubMed ID: 19747006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?
    Tran TB; Velkov T; Nation RL; Forrest A; Tsuji BT; Bergen PJ; Li J
    Int J Antimicrob Agents; 2016 Dec; 48(6):592-597. PubMed ID: 27793510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria.
    Evans ME; Feola DJ; Rapp RP
    Ann Pharmacother; 1999 Sep; 33(9):960-7. PubMed ID: 10492501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic evaluation of colistin sodium.
    Michalopoulos AS; Karatza DC; Gregorakos L
    Expert Opin Drug Metab Toxicol; 2011 Feb; 7(2):245-55. PubMed ID: 21128824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colistin and polymyxin B in critical care.
    Michalopoulos A; Falagas ME
    Crit Care Clin; 2008 Apr; 24(2):377-91, x. PubMed ID: 18361952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidrug-resistant Gram-negative bacteria: how to treat and for how long.
    Giamarellou H
    Int J Antimicrob Agents; 2010 Dec; 36 Suppl 2():S50-4. PubMed ID: 21129924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymyxins for CNS infections: Pharmacology and neurotoxicity.
    Velkov T; Dai C; Ciccotosto GD; Cappai R; Hoyer D; Li J
    Pharmacol Ther; 2018 Jan; 181():85-90. PubMed ID: 28750947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of antibacterial activities of polymyxin B and colistin against multidrug resistant Gram negative bacteria.
    Doymaz MZ; Karaaslan E
    Infect Dis (Lond); 2019 Sep; 51(9):676-682. PubMed ID: 31298061
    [No Abstract]   [Full Text] [Related]  

  • 16. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections.
    Li J; Nation RL; Turnidge JD; Milne RW; Coulthard K; Rayner CR; Paterson DL
    Lancet Infect Dis; 2006 Sep; 6(9):589-601. PubMed ID: 16931410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review.
    Zavascki AP; Goldani LZ; Li J; Nation RL
    J Antimicrob Chemother; 2007 Dec; 60(6):1206-15. PubMed ID: 17878146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of polymyxins: new insights into an 'old' class of antibiotics.
    Velkov T; Roberts KD; Nation RL; Thompson PE; Li J
    Future Microbiol; 2013 Jun; 8(6):711-24. PubMed ID: 23701329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colistin: an update on the antibiotic of the 21st century.
    Biswas S; Brunel JM; Dubus JC; Reynaud-Gaubert M; Rolain JM
    Expert Rev Anti Infect Ther; 2012 Aug; 10(8):917-34. PubMed ID: 23030331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous colistin sulfate: a rarely used form of polymyxin E for the treatment of severe multidrug-resistant Gram-negative bacterial infections.
    Huang J; Tang YQ; Sun JY
    Scand J Infect Dis; 2010 Apr; 42(4):260-5. PubMed ID: 20085424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.